Impact on the efficacy and safety of two target trough concentrations of Advagraf between 4 and 12 months post-transplantation in de novo renal transplant patients.

Trial Profile

Impact on the efficacy and safety of two target trough concentrations of Advagraf between 4 and 12 months post-transplantation in de novo renal transplant patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Nov 2016

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms ADEQUATE
  • Most Recent Events

    • 09 Nov 2016 Status changed from active, no longer recruiting to completed according to the results published in the American Journal of Transplantation.
    • 09 Nov 2016 Results published in the American Journal of Transplantation
    • 07 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top